Aratana Therapeutics to Present at Morgan Stanley Global Healthcare Conference

KANSAS CITY, Kan., Sept. 5, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced that it will present at the Morgan Stanley Global Healthcare Conference, to be held September 8-10, 2014, at the Grand Hyatt in New York City.

Steven St. Peter, M.D., President and Chief Executive Officer, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. 

Event:


Morgan Stanley Global Healthcare Conference

Date: 


Wednesday, September 10, 2014 

Time: 


10:55 am (Eastern Time) 

Location:


Grand Hyatt, New York, NY

The presentation will be webcast live and remain available for 30 days following the presentation.  To access the webcast, please visit the investor relations section of the Aratana website at aratana.investorroom.com.

About Aratana Therapeutics

Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The Company's pipeline includes more than fifteen therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions.  Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.

Contacts:
For investor inquires:
Aratana Therapeutics, Inc.
Craig Tooman
ctooman@aratana.com; (913) 353-1023

For media inquiries:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694

 

 

 

 

SOURCE Aratana Therapeutics, Inc.

print email rss